PBA
INCY icon

Paradigm Biocapital Advisors’s Incyte INCY Stock Holding History

Paradigm Biocapital Advisors’s Portfolio INCY Stock Details INCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-912,497
Closed -$52.7M – 33
2023
Q3 		$52.7M Sell
912,497
-469,214
-34% -$29.6M 3.58% 14
2023
Q2 		$86M Buy
1,381,711
+120,000
+10% +$8.02M 6.65% 2
2023
Q1 		$91.2M Buy
1,261,711
+408,881
+48% +$32M 8.64% 2
2022
Q4 		$68.5M Buy
852,830
+79,748
+10% +$6.1M 8.04% 1
2022
Q3 		$51.5M Buy
773,082
+217,039
+39% +$16M 6.87% 3
2022
Q2 		$42.2M Buy
556,043
+321,624
+137% +$24.4M 8.42% 5
2022
Q1 		$18.6M Buy
+234,419
New +$17.1M 4.92% 7

Other funds holding INCY

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Amundi
Amundi Paris, France $367B AUM 31.23% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Paradigm Biocapital Advisors's INCY Position: Q4 2023 in Review

Paradigm Biocapital Advisors sold out of Incyte (INCY) in Q4 2023, closing a stake of 912,497 shares — an estimated $52.7M sold.

Paradigm Biocapital Advisors first reported a position in INCY in Q1 2022 and held it in 7 quarters. The position peaked at $91.2M in Q1 2023. 556 funds tracked by Wall St. Rank hold INCY as of Q4 2023.

  • Paradigm Biocapital Advisors reported no remaining Incyte position as of Q4 2023 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 912,497 Incyte shares in Q4 2023, an estimated $52.7M.
  • Paradigm Biocapital Advisors first reported a position in Incyte in Q1 2022 and held it in 7 quarters.
  • Paradigm Biocapital Advisors's Incyte position peaked at $91.2M in Q1 2023.
  • 556 funds tracked by Wall St. Rank held Incyte as of Q4 2023.

Based on Paradigm Biocapital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.